Abivax's new ulcerative colitis data eases safety worries, sending shares up 25%
read at STAT ↗Positive readoutPositive
Abivax released additional data on its experimental ulcerative colitis drug obefazimod.
Earlier trial results had shown strong efficacy but raised safety concerns after several cancer cases were reported, which caused the company's shares to fall sharply.
The new analysis, presented in a group of hard-to-treat patients, confirmed the drug's efficacy and did not reveal new safety signals, helping to address earlier worries.
After the announcement, U.S.-listed shares of the French firm jumped roughly 25% overnight, reflecting renewed market confidence.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Abivax seeks to ease safety concerns with new data, boosting shares”
read at STAT ↗440 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that